GLP-1 Therapies May Modestly Reduce Global Liver Disease Burden

Metabolic dysfunction-associated steatotic liver disease, known as MASLD, has emerged as the leading cause of chronic liver disease worldwide, driven largely by the global rise in obesity and type 2 diabetes. Current estimates suggest that nearly one-third of the world’s adult population has some degree of this condition, with projections indicating that the burden will continue to increase in the coming decades. A hierarchical Bayesian forecast based on 245 studies involving approximately 2.7 million individuals estimated that the global adult prevalence of fatty liver disease would reach 55.7% by 2040, assuming that the trend observed in published prevalence studies continues. This expanding burden is expected to place substantial pressure on healthcare systems, reinforcing the need for effective and scalable strategies to prevent disease progression and reduce future healthcare demands.

The emergence of glucagon-like peptide-1 receptor agonists, or GLP-1RAs, and new incretin-based therapies may fundamentally alter this scenario. Initially developed for the treatment of type 2 diabetes, these agents have achieved levels of weight reduction and metabolic improvement that were previously difficult to attain pharmacologically. In the STEP 1 trial, semaglutide 2.4 mg once weekly produced a mean body weight reduction of 14.9% at 68 weeks, versus 2.4% with placebo. In the SURMOUNT-1 trial, tirzepatide produced mean reductions of 15.0%, 19.5%, and 20.9% with the 5-, 10-, and 15-mg doses, respectively, at 72 weeks, versus 3.1% with placebo. These results have raised an increasingly relevant question for hepatology and public health: could the widespread adoption of incretin-based therapies influence the future epidemiology of chronic liver disease?

The pivotal phase 3 ESSENCE trial randomized 1,197 patients with biopsy-defined MASH and fibrosis stage F2–F3 to semaglutide 2.4 mg once weekly or placebo. In the first 800 patients assessed at week 72, resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the treatment group versus 34.3% of the placebo group. Fibrosis improvement without worsening of steatohepatitis was observed in 36.8% versus 22.4%, respectively. These histological benefits supported accelerated or conditional regulatory approvals, with semaglutide receiving accelerated approval from the US Food and Drug Administration in August 2025 and a conditional marketing authorisation in the European Union in March 2026. However, the effects of these therapies on liver-related clinical outcomes remain unproven, as the endpoints in the ESSENCE trial were histological surrogates rather than hard clinical endpoints.

To translate this evidence into a public health perspective, researchers examined the potential impact fraction, a standard epidemiological measure of the proportional change in disease burden after a change in exposure. The model combined published estimates of eligibility, relative risk, treatment persistence, and effectiveness with coverage scenarios of 5%, 10%, and 20%. The results suggest relative reductions of approximately 0.3% to 1.1% in the global incidence of cirrhosis among individuals with prevalent MASLD, at equilibrium. These estimates represent testable hypotheses rather than established clinical effects, highlighting the gap between individual histological improvements and population-level epidemiological shifts.

Effective coverage, defined as coverage multiplied by persistence, is the principal constraint in this model. In a cohort of 125,474 US adults with overweight or obesity who initiated a GLP-1RA, 46.5% of those with and 64.8% of those without type 2 diabetes discontinued treatment within 1 year. Weight regain after treatment discontinuation appears to be common, suggesting that sustained therapy is necessary to maintain the long-term metabolic benefits. Because cirrhosis develops over decades, persistence over a 10- to 20-year horizon is unknown and unlikely to be higher than the short-term data suggest. This limitation significantly impacts the potential population-level benefit of these therapies.

The relationship between sustained weight reduction and improvement in MASLD is well established, with weight loss improving hepatic steatosis, reducing inflammatory activity, and improving insulin sensitivity. At the population level, the expected chain of effects is that if incretin-based therapies become broadly accessible, future reductions in obesity prevalence may translate into a lower incidence of hepatic steatosis and delayed progression to MASH. However, these changes are likely to emerge gradually over decades rather than years, reflecting the relatively slow progression of fibrosis and cirrhosis. The public health implications of this shift are significant, as MASLD is already a major source of healthcare expenditure due to cirrhosis management, transplantation, and hepatocellular carcinoma surveillance.

Access to incretin-based therapies remains highly unequal across countries and healthcare systems, with populations experiencing the fastest increase in obesity and MASLD often having the least access to advanced pharmacotherapy. High costs, reimbursement barriers, and limited healthcare infrastructure may restrict their broader implementation. Furthermore, although incretin-based therapies have consistently improved steatosis and metabolic dysfunction, their effects on advanced fibrosis remain less pronounced. In the ESSENCE trial, the absolute benefit on fibrosis improvement was approximately half that on steatohepatitis resolution, raising questions about whether these agents can substantially reduce the incidence of cirrhosis at the population level.

The future of MASLD management will likely depend on a shift from liver-centered treatment strategies to broader approaches focused on metabolic disease prevention. The recognition that adipose tissue dysfunction, visceral adiposity, sarcopenia, and systemic inflammation are major disease drivers highlights the need for integrated therapeutic models. Incretin-based therapies, which act on upstream metabolic drivers rather than on established liver disease, are among the first widely deployed pharmacological tools for which an effect on the epidemiology of chronic liver disease can be plausibly hypothesized and quantitatively tested. Whether this potential is realized depends on factors such as accessibility, affordability, long-term adherence, sustained efficacy, and effective healthcare policy implementation.

Whether the incretin era will ultimately lead to measurable reductions in cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related mortality remains unproven. The scenario presented by this research defines the magnitude of change that would be expected and, therefore, what future surveillance data would need to show. The incretin era has changed the conversation about MASLD, as hepatology is now considering not only how to treat steatohepatitis, but also whether the future burden of chronic liver disease itself can be modified. This shift marks an important departure from traditional hepatology, where most liver-directed therapies have focused on established diseases, often after fibrosis progression or cirrhosis had already developed.

Subject of Research: Epidemiological impact of GLP-1 therapies on MASLD

Article Title: Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective

Article References: Pereira, E. N. G. D. S., & Rodrigues, K. L. (2026). Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective. Frontiers in Endocrinology, 17, Article 1981916. https://doi.org/10.3389/fendo.2026.1981916

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1981916

Keywords: MASLD, GLP-1 receptor agonists, Obesity, Liver disease, Public health, Semaglutide, Tirzepatide, Cirrhosis, Metabolic dysfunction, Epidemiology, Will, GLP-1-based